Harold F. Dvorak

Q: What Schools Are Affiliated With Harold F. Dvorak

Harold F. Dvorak is affiliated with the following schools: Massachusetts Institute of Technology, University of Chicago, Massachusetts General Hospital, Harvard University

Harold F. Dvorak's AcademicInfluence.com Rankings

Harold F. Dvorak

Biology

#2430

World Rank

#3853

Historical Rank

#1086

USA Rank

Pathology

#19

World Rank

#54

Historical Rank

#11

USA Rank

biology Degrees

Download Badge

Biology

Harold F. Dvorak's Degrees

Doctorate Medicine University of Chicago

Why Is Harold F. Dvorak Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Harold Fisher Dvorak is an American pathologist and vascular researcher. He is the founding Director of the Center for Vascular Biology Research at the Beth Israel Deaconess Medical Center and the Mallinckrodt Distinguished Professor of Pathology at Harvard Medical School. Dvorak is best known for his discovery of vascular endothelial growth factor , for which he received the Canada Gairdner International Award of 2014.

(See a Problem?)

Harold F. Dvorak's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. (1983) (4042)
Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. (1986) (4037)
Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. (1995) (3281)
Analysis of nanoparticle delivery to tumours (2016) (3045)
Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. (2002) (1566)
Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 (2002) (1099)
Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. (1992) (954)
Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing (1992) (885)
Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. (1999) (775)
Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. (1994) (767)
Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. (1988) (735)
Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. (1993) (695)
Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis (1994) (693)
A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. (1986) (679)
Fibronectin and fibrin provide a provisional matrix for epidermal cell migration during wound reepithelialization. (1982) (675)
Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. (1995) (663)
T1α/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema (2003) (663)
Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. (1993) (602)
Vascular permeability factor (VPF, VEGF) in tumor biology (1993) (598)
Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue (1994) (567)
Vascular Permeability Factor/Vascular Endothelial Growth Factor Induces Lymphangiogenesis as well as Angiogenesis (2002) (563)
Vascular permeability, vascular hyperpermeability and angiogenesis (2008) (545)
Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. (1990) (537)
Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels (1991) (519)
Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. (1997) (499)
Transcellular diapedesis is initiated by invasive podosomes. (2007) (499)
Reappearance of an embryonic pattern of fibronectin splicing during wound healing in the adult rat (1989) (489)
Why are tumour blood vessels abnormal and why is it important to know? (2009) (475)
Tumors: Wounds That Do Not Heal—Redux (2015) (470)
Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. (1992) (470)
Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. (1987) (469)
Neutrophils Emigrate from Venules by a Transendothelial Cell Pathway in Response to FMLP (1998) (466)
Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. (1996) (458)
Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. (2006) (436)
Heterogeneity of the Angiogenic Response Induced in Different Normal Adult Tissues by Vascular Permeability Factor/Vascular Endothelial Growth Factor (2000) (428)
Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. (1989) (425)
Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. (1999) (394)
VEGF-A and the induction of pathological angiogenesis. (2007) (385)
Tumor-secreted vascular permeability factor increases cytosolic Ca2+ and von Willebrand factor release in human endothelial cells. (1991) (366)
Heterogeneity of the tumor vasculature. (2010) (365)
Osteopontin expression and distribution in human carcinomas. (1994) (361)
Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development. (1995) (360)
Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. (1995) (360)
The structure of normal skin and the morphology of atopic eczema. (1976) (358)
The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor (2001) (353)
Mast Cells Can Secrete Vascular Permeability Factor/ Vascular Endothelial Cell Growth Factor and Exhibit Enhanced Release after Immunoglobulin E–dependent Upregulation of Fcε Receptor I Expression (1998) (344)
Anti-VEGF/VEGFR therapy for cancer: reassessing the target. (2012) (332)
Inducer T lymphocytes synthesize a factor that stimulates proliferation of cloned mast cells (1981) (328)
Vascular Permeability Factor (VPF)/Vascular Endothelial Growth Factor (VEGF) Receptor-1 Down-modulates VPF/VEGF Receptor-2-mediated Endothelial Cell Proliferation, but Not Migration, through Phosphatidylinositol 3-Kinase-dependent Pathways* (2001) (322)
Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. (1995) (310)
Tumor shedding and coagulation. (1981) (295)
Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. (1995) (294)
Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin (1996) (291)
Vascular permeability factor mRNA and protein expression in human kidney. (1992) (285)
Hypoxia regulates the expression of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptors in human skin. (1997) (276)
Regulation of extravascular coagulation by microvascular permeability. (1985) (266)
The vesiculo‐vacuolar organelle (VVO): a distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation (1996) (265)
Differential expression of thymosin β‐10 by early passage and senescent vascular endothelium is modulated by VPF/VEGF: evidence for senescent endothelial cells in vivo at sites of atherosclerosis (2001) (254)
Vascular Permeability Factor, Fibrin, and the Pathogenesis of Tumor Stroma Formation a (1992) (251)
Fibroblast migration in fibrin gel matrices. (1993) (248)
Angiogenesis Therapy: Amidst the Hype, the Neglected Potential for Serious Side Effects (2001) (246)
Induction of a fibrin-gel investment: an early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products. (1979) (245)
Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells. (1995) (243)
CUTANEOUS BASOPHIL HYPERSENSITIVITY : II. A LIGHT AND ELECTRON MICROSCOPIC DESCRIPTION (1970) (238)
Stable Expression of Angiopoietin-1 and Other Markers by Cultured Pericytes: Phenotypic Similarities to a Subpopulation of Cells in Maturing Vessels During Later Stages of Angiogenesis In Vivo (2002) (234)
Morphology of delayed type hypersensitivity reactions in man. I. Quantitative description of the inflammatory response. (1974) (230)
Vascular permeability factor (Vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast (1997) (228)
Pathways of macromolecular tracer transport across venules and small veins. Structural basis for the hyperpermeability of tumor blood vessels. (1992) (226)
Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma. (2003) (224)
Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. (1991) (222)
Fibrin gel investment associated with line 1 and line 10 solid tumor growth, angiogenesis, and fibroplasia in guinea pigs. Role of cellular immunity, myofibroblasts, microvascular damage, and infarction in line 1 tumor regression. (1979) (222)
Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery. (2001) (222)
ROLE OF THE CLOTTING SYSTEM IN CELL-MEDIATED HYPERSENSITIVITY (1973) (214)
Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. (1996) (213)
Blood vessel fibronectin increases in conjunction with endothelial cell proliferation and capillary ingrowth during wound healing. (1982) (212)
Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. (1993) (210)
Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. (1983) (207)
Basophils and Mast Cells: Morphologic Insights into Their Biology, Secretory Patterns, and Function1 (1984) (205)
Macrophages and fibroblasts express embryonic fibronectins during cutaneous wound healing. (1993) (197)
Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. (1989) (195)
Lipid bodies: cytoplasmic organelles important to arachidonate metabolism in macrophages and mast cells. (1983) (194)
Pathways of Macromolecular Extravasation Across Microvascular Endothelium in Response to VPF/VEGF and Other Vasoactive Mediators (1999) (192)
Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting (2007) (191)
Tumor microenvironment and progression (2011) (181)
Morphology of delayed-type hypersensitivity reactions in man. (1976) (179)
Forty-Year Journey of Angiogenesis Translational Research (2011) (178)
Macrophage migration in fibrin gel matrices. (1986) (178)
Pathogenesis of ascites tumor growth: angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining. (1995) (178)
Morphology of delayed-type hypersensitivity reactions in man. II. Ultrastructural alterations affecting the microvasculature and the tissue mast cells. (1976) (177)
Defective Associations between Blood Vessels and Brain Parenchyma Lead to Cerebral Hemorrhage in Mice Lacking αv Integrins (2002) (174)
Mast cell clones: a model for the analysis of cellular maturation (1982) (172)
Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. (2005) (167)
Fibrin as a component of the tumor stroma: origins and biological significance (2004) (161)
VEGF-A(164/165) and PlGF: roles in angiogenesis and arteriogenesis. (2003) (158)
The von Hippel-Lindau Gene Product Inhibits Vascular Permeability Factor/Vascular Endothelial Growth Factor Expression in Renal Cell Carcinoma by Blocking Protein Kinase C Pathways* (1997) (158)
Overexpression of vascular permeability factor (VPF/VEGF) and its endothelial cell receptors in delayed hypersensitivity skin reactions. (1995) (158)
Orphan nuclear receptor TR3/Nur77 regulates VEGF-A–induced angiogenesis through its transcriptional activity (2006) (156)
Expression of Tie1, Tie2, and angiopoietins 1, 2, and 4 in Kaposi's sarcoma and cutaneous angiosarcoma. (2000) (156)
Vascular hyperpermeability, angiogenesis, and stroma generation. (2012) (155)
Vessel co‐option is common in human lung metastases and mediates resistance to anti‐angiogenic therapy in preclinical lung metastasis models (2016) (155)
Increased expression of vascular permeability factor (vascular endothelial growth factor) in bullous pemphigoid, dermatitis herpetiformis, and erythema multiforme. (1995) (152)
Discovery of vascular permeability factor (VPF). (2006) (152)
Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets (2012) (149)
VPF/VEGF and the angiogenic response. (2000) (149)
Role of the clotting system in cell-mediated hypersensitivity. II. Kinetics of fibrinogen/fibrin accumulation and vascular permeability changes in tuberculin and cutaneous basophil hypersensitivity reactions. (1975) (146)
Two distinct cellular patterns in cutaneous necrotizing angiitis. (1976) (139)
Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma (1996) (139)
Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma. (1996) (138)
Rejection of first-set skin allografts in man. the microvasculature is the critical target of the immune response (1979) (136)
Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) delays and induces escape from senescence in human dermal microvascular endothelial cells (1997) (134)
Leaky vessels, fibrin deposition, and fibrosis: a sequence of events common to solid tumors and to many other types of disease. (1989) (132)
Correlation of vascular permeability factor/vascular endothelial growth factor with extraretinal neovascularization in the rat. (1996) (131)
The late phase skin reaction: evidence for activation of the coagulation system in an IgE-dependent reaction in man. (1979) (131)
Basophilic leukocytes in allergic contact dermatitis. (1972) (125)
Ultrastructural localization of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) to the abluminal plasma membrane and vesiculovacuolar organelles of tumor microvascular endothelium. (1995) (123)
Thrombosis and cancer. (1987) (121)
Macrophage migration in fibrin gel matrices. II. Effects of clotting factor XIII, fibronectin, and glycosaminoglycan content on cell migration. (1988) (120)
Cloning of DLM-1, a novel gene that is up-regulated in activated macrophages, using RNA differential display. (1999) (118)
Ultrastructural Localization of the Vascular Permeability Factor/Vascular Endothelial Growth Factor (VPF/VEGF) Receptor-2 (FLK-1, KDR) in Normal Mouse Kidney and in the Hyperpermeable Vessels Induced by VPF/VEGF-expressing Tumors and Adenoviral Vectors (2000) (118)
Reinterpretation of endothelial cell gaps induced by vasoactive mediators in guinea‐fig, mouse and rat: many are transcellular pores (1997) (117)
Fibrinogen influx and accumulation of cross-linked fibrin in healing wounds and in tumor stroma. (1988) (116)
A secreted phosphoprotein marker for neoplastic transformation of both epithelial and fibroblastic cells (1983) (115)
Basophils and mast cells: morphologic insights into their biology, secretory patterns, and function. (1984) (111)
VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation. (2009) (110)
Ultrastructural studies define soluble macromolecular, particulate, and cellular transendothelial cell pathways in venules, lymphatic vessels, and tumor‐associated microvessels in man and animals (2002) (108)
Alterations in proteoglycan synthesis common to healing wounds and tumors. (1991) (108)
Fibrinogen/fibrin on the surface of macrophages: detection, distribution, binding requirements, and possible role in macrophage adherence phenomena (1975) (107)
Human breast carcinoma: fibrin deposits and desmoplasia. Inflammatory cell type and distribution. Microvasculature and infarction. (1981) (106)
Cytoplasmic lipid bodies of human eosinophils. Subcellular isolation and analysis of arachidonate incorporation. (1991) (105)
Vascular permeability factor/vascular endothelial growth factor inhibits anchorage-disruption-induced apoptosis in microvessel endothelial cells by inducing scaffold formation. (1997) (105)
Thrombospondin‐1 modulates vascular endothelial growth factor activity at the receptor level (2009) (104)
Different pathways of macromolecule extravasation from hyperpermeable tumor vessels. (2000) (103)
Ultrastructural identification of the mouse basophil. (1982) (103)
Cutaneous basophil hypersensitivity. I. A new look at the Jones-Mote reaction, general characteristics. (1970) (103)
Vascular permeability factor/vascular endothelial growth factor-mediated signaling in mouse mesentery vascular endothelium. (1998) (102)
Tumor cell generation of thrombin via functional prothrombinase assembly. (1985) (102)
Fibronectin in delayed-type hypersensitivity skin reactions: associations with vessel permeability and endothelial cell activation. (1981) (100)
Permeability properties of tumor surrogate blood vessels induced by VEGF-A (2006) (98)
Vascular permeability factor/vascular endothelial growth factor and its receptors in oral and laryngeal squamous cell carcinoma and dysplasia. (1997) (96)
Loss of cell surface material from peritoneal exudate cells associated with lymphocyte-mediated inhibition of macrophage migration from capillary tubes. (1972) (95)
VEGF-A induces angiogenesis, arteriogenesis, lymphangiogenesis, and vascular malformations. (2002) (95)
Vascular permeability factor, tumor angiogenesis and stroma generation. (1994) (93)
Quantitation of fibrinogen influx and fibrin deposition and turnover in line 1 and line 10 guinea pig carcinomas. (1984) (93)
Degranulation of basophilic leukocytes in allergic contact dermatitis reactions in man. (1976) (91)
Vascular permeability factor (vascular endothelial growth factor) is strongly expressed in the normal male genital tract and is present in substantial quantities in semen. (1995) (91)
Rapamycin Inhibition of the Akt/mTOR Pathway Blocks Select Stages of VEGF-A164–Driven Angiogenesis, in Part by Blocking S6Kinase (2009) (90)
Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid tumors. (1992) (89)
Vascular permeability and pathological angiogenesis in caveolin-1-null mice. (2009) (88)
Tumor Stroma, Tumor Blood Vessels, and Antiangiogenesis Therapy. (2015) (88)
Pathogenesis of ascites tumor growth: fibrinogen influx and fibrin accumulation in tissues lining the peritoneal cavity. (1995) (88)
A quantitative analysis of tumor specific monoclonal antibody uptake by human melanoma xenografts: effects of antibody immunological properties and tumor antigen expression levels. (1992) (87)
Pathogenesis of malignant ascites formation: initiating events that lead to fluid accumulation. (1993) (87)
Cutaneous basophil hypersensitivity. 3. Participation of the basophil in hypersensitivity to antigen-antibody complexes, delayed hypersensitivity and contact allergy. Passive transfer. (1971) (87)
Increased hyaluronan at sites of attachment to mesentery by CD44-positive mouse ovarian and breast tumor cells. (1996) (87)
ANTIGEN-INDUCED STIMULATION OF GLUCOSAMINE INCORPORATION BY GUINEA PIG PERITONEAL MACROPHAGES IN DELAYED HYPERSENSITIVITY (1972) (86)
Purification and properties of two acid phosphatase fractions isolated from osmotic shock fluid of Escherichia coli. (1967) (83)
Differences in the behavior of cytoplasmic granules and lipid bodies during human lung mast cell degranulation (1984) (83)
Cellular and vascular manifestations of cell-mediated immunity. (1986) (82)
Caveolae and Vesiculo-Vacuolar Organelles in Bovine Capillary Endothelial Cells Cultured with VPF/VEGF on Floating Matrigel-collagen Gels (1999) (81)
Glycosylation is essential for efficient secretion but not for permeability-enhancing activity of vascular permeability factor (vascular endothelial growth factor). (1991) (80)
Chemotaxis of basophils by lymphocyte-dependent and lymphocyte-independent mechanisms. (1975) (79)
Ultrastructural localization of nonspecific esterase activity in guinea pig and human monocytes, macrophages, and lymphocytes. (1981) (79)
The L6 protein TM4SF1 is critical for endothelial cell function and tumor angiogenesis. (2009) (79)
T cell subsets in allograft rejection. In situ characterization of T cell subsets in human skin allografts by the use of monoclonal antibodies. (1982) (78)
Basophil and mast cell degranulation: ultrastructural analysis of mechanisms of mediator release. (1983) (78)
The vascular permeabilizing factors histamine and serotonin induce angiogenesis through TR3/Nur77 and subsequently truncate it through thrombospondin-1. (2013) (78)
Delayed-type hypersensitivity skin reactions in congenital afibrinogenemia lack fibrin deposition and induration. (1979) (77)
Down Syndrome Candidate Region 1 Isoform 1 Mediates Angiogenesis through the Calcineurin-NFAT Pathway (2006) (77)
Secretion of vascular endothelial growth factor/vascular permeability factor from human luteinized granulosa cells is human chorionic gonadotrophin dependent. (1998) (76)
Osteopontin is strongly expressed by histiocytes in granulomas of diverse etiology. (1997) (76)
Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy. (2011) (75)
Dermal hypersensitivity reactions to imported fire ants. (1984) (74)
Inhibition of vascular permeability factor (vascular endothelial growth factor) with antipeptide antibodies. (1993) (72)
The association between tumour progression and vascularity in myxofibrosarcoma and myxoid/round cell liposarcoma (2000) (72)
Basophilic leucocytes: structure, function and role in disease. (1975) (72)
Exchange of macromolecules between plasma and peritoneal cavity in ascites tumor-bearing, normal, and serotonin-injected mice. (1989) (69)
CUTANEOUS BASOPHIL HYPERSENSITIVITY (1970) (68)
Antigen-induced IgE-mediated degranulation of human basophils. (1980) (66)
Vascular permeability to plasma, plasma proteins, and cells: an update (2010) (66)
Fibronectin beneath reepithelializing epidermis in vivo: sources and significance. (1983) (66)
Melanoma. An ultrastructural study of the host inflammatory and vascular responses. (1980) (65)
IMMUNOLOGIC REJECTION OF DIETHYLNITROSAMINE-INDUCED HEPATOMAS IN STRAIN 2 GUINEA PIGS (1973) (65)
Cytochemical Localization of Certain Phosphatases in Escherichia coli (1970) (64)
Immunologic rejection of mammary adenocarcinoma (TA3-St) in C57BL/6 mice: participation of neutrophils and activated macrophages with fibrin formation. (1978) (64)
Physical nanoscale conduit-mediated communication between tumour cells and the endothelium modulates endothelial phenotype (2015) (63)
Fibrinogen influx and accumulation of cross-linked fibrin in mouse carcinomas. (1988) (63)
Leaky tumor vessels: consequences for tumor stroma generation and for solid tumor therapy. (1990) (61)
Dermal hypersensitivity reactions to insulin: correlations of three patterns to their histopathology. (1982) (61)
Ultrastructural Localization of Platelet Endothelial Cell Adhesion Molecule (PECAM-1, CD31) in Vascular Endothelium (2004) (61)
Ultrastructural localization of prostaglandin endoperoxide synthase (cyclooxygenase) to isolated, purified fractions of guinea pig peritoneal macrophage and line 10 hepatocarcinoma cell lipid bodies. (1993) (60)
BASOPHILS AND MAST CELLS IN RENAL ALLOGRAFT REJECTION (1974) (59)
Penetration of Tumor Tissue by Antibodies and Other Immunoproteins (1991) (58)
Proteolytic Cleavage of Versican and Involvement of ADAMTS-1 in VEGF-A/VPF-Induced Pathological Angiogenesis (2011) (58)
Tissue factor activity of normal and neoplastic cells: quantitation and species specificity. (1983) (56)
Cloned mouse cells with natural killer function and cloned suppressor T cells express ultrastructural and biochemical features not shared by cloned inducer T cells (1983) (55)
Anaphylactic degranulation of guinea pig basophilic leukocytes. I. Fusion of granule membranes and cytoplasmic vesicles formation and resolution of degranulation sacs. (1981) (54)
Orphan nuclear transcription factor TR3/Nur77 regulates microvessel permeability by targeting endothelial nitric oxide synthase and destabilizing endothelial junctions (2011) (53)
TM4SF1: a tetraspanin-like protein necessary for nanopodia formation and endothelial cell migration (2011) (53)
Systemic expression of cutaneous basophil hypersensitivity. (1977) (52)
Uptake of horseradish peroxidase by guinea pig basophilic leukocytes. (1972) (52)
Sulfated glycosaminoglycans of guinea pig basophilic leukocytes. (1978) (50)
Compartmental distribution of tumor-specific monoclonal antibodies in human melanoma xenografts. (1994) (50)
VEGF‐A Angiogenesis Induces a Stable Neovasculature in Adult Murine Brain (2004) (49)
Platelets Exit Venules by a Transcellular Pathway at Sites of F–Met Peptide–Induced Acute Inflammation in Guinea Pigs (1998) (48)
Cutaneous basophilic hypersensitivity: a new interpretation of the Jones-Mote reaction. (1969) (48)
Circulating membrane vesicles in leukemic blood. (1985) (47)
Role of the basophilic leukocyte in allograft rejection. (1971) (47)
Pathogenesis of desmoplasia. I. Immunofluorescence identification and localization of some structural proteins of line 1 and line 10 guinea pig tumors and of healing wounds. (1984) (46)
Differences in the volume distributions of human lung mast cell granules and lipid bodies: evidence that the size of these organelles is regulated by distinct mechanisms (1985) (45)
IMMUNOLOGIC UNRESPONSIVENESS IN THE ADULT GUINEA PIG. I. SUPPRESSION OF DELAYED HYPERSENSITIVITY AND ANTIBODY FORMATION TO PROTEIN ANTIGENS. (1965) (45)
Fibrin deposits in Hodgkin's disease. (1982) (45)
Evidence for a vesicular transport mechanism in guinea pig basophilic leukocytes. (1980) (44)
Vascular targeting of solid and ascites tumours with antibodies to vascular endothelial growth factor. (1996) (44)
A cloned cell with NK function resembles basophils by ultrastructure and expresses IgE receptors (1982) (44)
Nerve growth factor: a protease that can activate plasminogen. (1978) (44)
Mast cells in the cortical tubular epithelium and interstitium in human renal disease. (1974) (43)
BASOPHILIC LEUKOCYTES IN ALLERGIC CONTACT DERMATITIS (1972) (41)
Expression of cell-mediated hypersensitivity in vivo--recent advances. (1980) (41)
Cutaneous basophil hypersensitivity. (1976) (41)
Cutaneous necrotizing venulitis: a sequential analysis of the morphological alterations occurring after mast cell degranulation in a patient with a unique syndrome. (1978) (41)
Ultrastructural criteria for identification of mast cells and basophils in humans, guinea pigs, and mice. (1983) (40)
Biochemical and Cytochemical Evidence for the Polar Concentration of Periplasmic Enzymes in a “Minicell” Strain of Escherichia coli (1970) (39)
Basophils, mast cells, and cellular immunity in animals and man. (1972) (37)
Metallo-enzymes released from Escherichia coli by osmotic shock. II. Evidence that 5'-nucleotidase and cyclic phosphodiesterase are zinc metallo-enzymes. (1968) (37)
Tumors: Wounds That Do Not Heal—A Historical Perspective with a Focus on the Fundamental Roles of Increased Vascular Permeability and Clotting (2019) (36)
Myocardial fibrin deposition in experimental viral myocarditis that progresses to dilated cardiomyopathy. (1993) (36)
Retinoic acid selectively inhibits the vascular permeabilizing effect of VPF/VEGF, an early step in the angiogenic cascade. (2000) (36)
TM4SF1: a new vascular therapeutic target in cancer (2014) (35)
Lymphokines as Inflammatory Mediators (1979) (34)
Lipid Bodies: Widely Distributed Cytoplasmic Structures That Represent Preferential Nonmembrane Repositories of Exogenous [3H]Arachidonic Acid Incorporated by Mast Cells, Macrophages, and Other Cell Types (1985) (34)
Revealing the role of phospholipase Cβ3 in the regulation of VEGF-induced vascular permeability. (2012) (33)
Role of basophilic leukocytes in cellular immunity to vaccinia virus infection. (1971) (33)
Plasminogen activator of guinea pig basophilic leukocytes: probable localization to the plasma membrane. (1978) (33)
Stromal-Based Signatures for the Classification of Gastric Cancer. (2016) (32)
Principles of Cancer Pathology (2003) (32)
Bystander suppression of tumor growth: evidence that specific targets and bystanders are damaged by injury to a common microvasculature. (1982) (32)
Purification of basophilic leukocytes from guinea pig blood and bone marrow. (1974) (31)
Role of BRAFV600E in the first preclinical model of multifocal infiltrating myopericytoma development and microenvironment. (2014) (31)
HETEROGENEITY OF THE CELLULAR IMMUNE RESPONSE (1971) (31)
MIF-Like Activity in Simian Virus 40-Transformed 3T3 Fibroblast Cultures (1974) (31)
Fibronectin beneath reepithelializing epidermis in vivo: sources and significance. (1983) (31)
Novel Anti-TM4SF1 Antibody–Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature (2015) (31)
Basophils and Mast Cells: Structure, Function, and Role in Hypersensitivity (1979) (30)
Role of the Surgical Pathologist in the Diagnosis and Management of the Cancer Patient (2003) (28)
Anaphylactic degranulation of guinea pig basophilic leukocytes. II. Evidence for regranulation of mature basophils during recovery from degranulation in vitro. (1982) (28)
Spatial distribution of tumor-specific monoclonal antibodies in human melanoma xenografts. (1992) (28)
Failure of Hypnotic Suggestion to Alter Immune Response to Delayed‐Type Hypersensitivity Antigens a (1987) (28)
The microvasculature is the critical target of the immune response in vascularized skin allograft rejection. (1980) (27)
Tumor-basophil interactions in vitro--a scanning and transmission electron microscopic study. (1979) (26)
Antigen-enhanced glucosamine incorporation by peritoneal macrophages in cell-mediated hypersensitivity. I. Studies on biology and mechanism. (1975) (26)
Chapter 3. The adenoviral vector angiogenesis/lymphangiogenesis assay. (2008) (25)
HETEROGENEITY OF THE CELLULAR IMMUNE RESPONSE (1971) (25)
Morphology of delayed-type hypersensitivity reactions in the guinea pig cornea. (1977) (25)
The "transfer reaction" in the rabbit. II. A radioautographic study. (1963) (25)
Cutaneous basophil hypersensitivity. IV. The "late reaction": sequel to Jones-Mote type hypersensitivity. Comparison with rabbit Arthus reaction. Effect of passive antibody on induction and expression of Jones-Mote hypersensitivity. (1973) (24)
Metabolic studies of guinea pig basophilic leukocytes in short-term tissue culture. I. Measurement of histaminesynthesizing capacity by using an isotopic-thin layer chromatographic assay. (1976) (23)
Specificity of basophils and lymphocytes in cutaneous basophil hypersensitivity. (1975) (23)
Ultrastructural Immunogold Localization of Osteopontin in Human Gastric Mucosa (1997) (23)
Quantitative measurements of neutral red uptake and excretion by mammalian cells. (1980) (23)
Enzymatic inactivation of immunologically competent lyph node cells in the "transfer reaction". (1962) (23)
The occurrence of a protein inhibitor for 5'-nucleotidase in extracts of Escherichia coli. (1966) (22)
CUTANEOUS BASOPHIL HYPERSENSITIVITY (1970) (22)
Ultrastructural immunogold localization of osteopontin in human gallbladder epithelial cells. (1994) (22)
The late phase skin reaction: paradigm or epiphenomena? (1983) (22)
Vascular Permeability Factor/Vascular Endothelial Growth Factor and Vascular Stroma Formation in Neoplasia: Insights from In Situ Hybridization Studies (1998) (22)
The negative tuberculin test: tuberculin, HIV, and anergy panels. (1995) (21)
Roles in Angiogenesis and Arteriogenesis (2003) (21)
Preparation of a rabbit anti-guinea pig basophil serum: in vitro and in vivo characterization. (1978) (21)
Structure of Freund's complete and incomplete adjuvants. Relation of adjuvanticity to structure. (1974) (20)
Cytochemical localization of peroxidase activity in the developing erythrocyte. (1972) (20)
Fibronectin deposition in delayed-type hypersensitivity. Reactions of normals and a patient with afibrinogenemia. (1984) (20)
A multi-gene transcriptional profiling approach to the discovery of cell signature markers (2010) (20)
Nagy JA, Herzberg KT, Dvorak JM, Dvorak HFPathogenesis of malignant ascites formation: initiating events that lead to fluid accumulation. Cancer Res 53(11): 2631-2643 (1993) (20)
Immunologic unresponsiveness in the adult guinea pig. II. The kinetics of unresponsiveness. (1966) (19)
Generation of macrophage migration inhibitory activity by plasminogen activators. (1977) (18)
Morphologic changes in draining lymph nodes and in lymphocyte cultures after sensitization with complete or incomplete Freund's adjuvant. Correlation with immunologic events in vivo and in culture. (1971) (18)
Tumor Structure and Tumor Stroma Generation (2003) (17)
Orphan nuclear receptor TR 3 / Nur 77 regulates VEGF-A – induced angiogenesis through its transcriptional activity (2006) (17)
Tumor Blood Vessels (2008) (16)
Nonspecific esterase activity expressed in Weibel-Palade bodies of cloned guinea pig aortic endothelial cells. (1987) (16)
Early Actions of Anti-Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Drugs on Angiogenic Blood Vessels. (2017) (16)
Isolation of the cytoplasmic granules of guinea pig basophilic leukocytes: identification of esterase and protease activities. (1977) (15)
Basophils and Mast Cells: Morphologic Insights into Their Biology, Secretory Patterns, and Function (Part 1 of 7) (1984) (14)
Degranulation mechanisms in human leukemic basophils. (1976) (14)
The fate of antigen in delayed hypersensitivity skin reactions. (1970) (14)
125I-fibrin deposition in contact sensitivity reactions in the mouse. Sensitivity of the assay for quantitating reactions after active or passive sensitization. (1986) (14)
PRIMARY IMMUNIZATION OF LYMPH NODE CELLS IN MILLIPORE CHAMBERS BY EXPOSURE TO HOMOGRAFT ANTIGEN (1962) (14)
The basophil. Its morphology, biochemistry, motility, release reactions, recovery, and role in the inflammatory responses of IgE-mediated and cell-mediated origin. (1979) (14)
Letter: Basophils and mast cells in renal allograft rejection. (1974) (14)
Cryptic and active plasminogen activators secreted by line 10 tumor cells in culture. (1983) (13)
Mouse mast cell clones: modulation of functional maturity in vitro. (1983) (13)
Immunologic unresponsiveness in the adult guinea pig. 3. Variation of the antigen and vehicle of suppression. Induction of unresponsiveness in the adult rat. (1966) (13)
Fibrin Formation: Implications for Tumor Growth and Metastasis (1984) (13)
Fibrin deposition in autochthonous Syrian hamster pancreatic adenocarcinomas induced by the chemical carcinogen N-nitroso-bis(2-oxopropyl)amine. (1987) (13)
Ultrastructural studies of macrophages: in vitro removal of cell coat with macrophage inhibition factor (MIF)-containing lymphocyte culture supernatants; chloroform extraction, phospholipase digestion, and autoradiographic studies. (1980) (12)
LOCALIZATION OF SKELETAL MUSCLE PHOSPHORYLASE USING A FLUORESCENT ANTIBODY TECHNIQUE AND ITS CORRELATION WITH HISTOCHEMICAL OBSERVATIONS (1965) (12)
Nature of the immunogen in crystalline serum albumins. (1970) (12)
Immunologic unresponsiveness in the adult guinea pig. IV. Induction of unresponsiveness with aggregated serum proteins. (1969) (12)
Histamine and basophils in delayed-type hypersensitivity reactions. (1973) (11)
Metallo-enzymes released from Escherichia coli by osmotic shock. I. Selective depression of enzymes in cells grown in the presence of ethylenediaminetetraacetate. (1968) (11)
Reconciling VEGF With VPF: The Importance of Increased Vascular Permeability for Stroma Formation in Tumors, Healing Wounds, and Chronic Inflammation (2021) (11)
Potential Functions of the Clotting System in Wound Repair (1998) (11)
Surface membrane alterations in guinea pig basophils undergoing anaphylactic degranulation. A scanning electron microscopic study. (1981) (10)
Guinea pig basophil morphology in vitro. I. Ultrastructure of uropod-bearing (motile) basophils and modulation of motile structures by serum and substrate effects. (1981) (10)
Pathogenesis of tumor desmoplasia. II. Collagens synthesized by line 1 and line 10 guinea pig carcinoma cells and by syngeneic fibroblasts in vitro. (1984) (9)
Intracellular distribution of TM4SF1 and internalization of TM4SF1-antibody complex in vascular endothelial cells. (2015) (8)
The L 6 Protein TM 4 SF 1 Is Critical for Endothelial Cell Function and Tumor Angiogenesis (2009) (8)
TM 4 SF 1 : a new vascular therapeutic target in cancer (2014) (8)
Basophilic leukocytes in delayed-type hypersensitivity reactions in experimental animals and man. (1973) (8)
Ultrastructural cytochemical and autoradiographic demonstration of nonspecific esterase(s) in guinea pig basophils. (1987) (7)
Basophilic leukocytes in a case of poison ivy. (1971) (7)
Esterase and protease activity of purified guinea pig basophil granules. (1976) (6)
Surface membrane traffic in guinea pig basophils exposed to cationic ferritin. (1985) (6)
Glycosaminoglycans and proteases of guinea pig basophilic leukocytes. (1981) (5)
Purification of Basophilic Leukocytes from Guinea Pig and Human Blood and from Guinea Pig Bone Marrow (1982) (5)
193. The late-phase skin reaction (1978) (4)
Cytochemical Localization ofCertain Phosphatases inEscherichia coli (1970) (4)
A role for cytoplasmic vesicles in anaphylactic degranulation of guinea pig basophils. (1981) (4)
Endothelial Biomedicine: Tumor Blood Vessels (2007) (4)
Inbred guinea pig aortic endothelial cell clones. Model for studying the vascular endothelium under totally isologous conditions. (1986) (4)
The “transfer reaction” in the rabbit. II (1964) (3)
Macrophage procoagulants and microvascular permeability: roles in the extravascular coagulation of cellular immunity (1985) (3)
PATIENTS WITHOUT BASOPHILS (1977) (3)
EFFECT OF MACROPHAGES ON PRIMARY IMMUNIZATION OF LYMPH NODE CELLS AGAINST HOMOGRAFTS IN DIFFUSION CHAMBERS. (1966) (3)
Effect of Macrophages on Primary Immunization of Lymph Node Cells Against Homografts in Diffusion Chambers.∗ (1964) (3)
Hapten-specific delayed hypersensitivity to epsilon-2,4-dinitrophenyl-L- lysine-Ficoll in guinea pigs immunized with 2,4-dinitrophenyl-keyhole limpet hemocyanin (1977) (3)
Proceedings: Morphologic studies in cellular hypersensitivity in guinea pigs and man. (1974) (3)
Expression of vascular permeability factor (vascular endothelial growth factor) by human corpus luteal cells: Possible role in corpus luteum development (1993) (2)
Letter: Cause of induration in skin tests (cont.). (1976) (2)
Plasminogen activator and MIF-like activities in Kirsten virus transformed mouse NIH culture fluids. (1978) (2)
Special issues of systemic treatments (2002) (2)
Alteration of aliphatic lipid proton NMR linewidths by malignant tumors in guinea pigs. (1990) (2)
My friend Marty (2010) (2)
CRITICAL ISSU-ES IN TUMOR MICROCIRCULATION, ANGIOGENESIS AND METASTASIS: BIOLOGICAL SIGNIFICANCE AND CLINICAL RELEVANCE (1993) (2)
403 Fibrin(ogen) influx, accumulation and degradation in peritoneal walls/cavaties of guinea pigs/mice bearing ascites tumors (lines 1 & 10, TA3/St, MOT) (1988) (2)
Basophils and Mast Cells: Morphologic Insights into Their Biology, Secretory Patterns, and Function (Part 6 of 7) (1984) (2)
Effect of E-amino caproic acid on macrohage cell coat and migration inhibtion. (1978) (1)
Ultrastructural Cytochemical and Autoradiographic (1987) (1)
Abstract IA01: Heterogeneity of the tumor vasculature: Why doesn't anti-VEGF/VEGF receptor therapy work better? (2015) (1)
Peritoneal fluid factor that inhibits cell adherence (1976) (1)
Plasminogen activator of guinea pig basophils. A protease probably localized to the cell surface. (1979) (1)
Effect of Ribonuclease Upon Immunologically Active Cells.∗ (1961) (1)
Mouse mast cells and other granulated leukocyte clones. Ultrastructure of cloned mouse leukocytes. (1983) (1)
Subcellular Isolation andAnalysis ofArachidonate Incorporation (1991) (1)
Serotonin (5ht) uptake and content of cloned mouse mast cells and mouse peritoneal mast cells. Abstr. (1983) (1)
Basophils and Mast Cells: Morphologic Insights into Their Biology, Secretory Patterns, and Function (Part 7 of 7) (1984) (1)
Discovery of Vascular Permeability Factor (VPF, VEGF, VPF/VEGF, VEGF-A165) (2009) (1)
CirculatingMembraneVesicles in LeukemicBlood 1 (2006) (0)
Discoveries Interview: Professor Harold F. Dvorak on the discovery of Vascular Endothelial Growth Factor (VEGF) (2016) (0)
Functional aspects of the ultrastructure of vessels in transplanted tumors (1991) (0)
FIBRIN FORMATION: IMPLICATIOIIS FOR TUMOR GROWTH AND (1984) (0)
TM4SF1: a new vascular therapeutic target in cancer (2014) (0)
Angiogenesis in Neoplasia; Insights from in Situ Hybridization Studies (1997) (0)
Ultrastructure of the cell coat of untransformed and simian virus 40-transformed fibroblasts. (1979) (0)
Vascular P ermeability F actor/Vascular E ndothelial G rowth Factor: A C ritical C ytokine i n T umor A ngiogenesis a nd a Potential T arget f or D iagnosis a nd T herapy (2002) (0)
H. THE ROLE OF ADJUVANT. LYMPHOCYTE STIMULATION IN CUTANEOUS BASOPHIL HYPERSENSITIVITY* (2003) (0)
Comparison of the Biological Activities of VEGF Isoforms (2007) (0)
Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets (2012) (0)
I. a New Loo~: at ]_'he Joz~ts-morx Reaction, General Characteristics* (0)
0bituary: Dr. Louis Dienes. (1974) (0)
Abstract 2359: Bioinformatics analysis of an Ad-VEGF flank angiogenesis model identifies vessel subtype gene signatures: Implications for anti-VEGF therapy (2014) (0)
Immunologic Unresponsiveness in the Adult Guinea Pig (1965) (0)
Abstract 4810: Identification of molecular markers of pathological vascular subtypes with differential sensitivity to therapies targeting the VEGF pathway (2014) (0)
Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A driven angiogenesis in part through the blockade of S6Kinase (2008) (0)
Critical issues in Tumor microcirculation, Angiogenesis and Metastasis: Biological significance and clinical relevance (2004) (0)
Patents And literature (1985) (0)
CirculatingMembraneVesicles in LeukemicBlood1 (2006) (0)
AKT/PKB REGULATES MICROVASCULAR REMODELING AND HOMEOSTASIS (2004) (0)
Basophils and Mast Cells: Morphologic Insights into Their Biology, Secretory Patterns, and Function (Part 5 of 7) (1984) (0)
Disseminated intravascular coagulation. (1969) (0)
Function and Tumor Angiogenesis The L 6 Protein TM 4 SF 1 Is Critical for Endothelial Cell (2009) (0)
Differences in the Behavior Lipid Bodies during Human of Cytoplasmic Granules and Lung Mast Cell Degranulation (2003) (0)
A preliminary investigation into the histocompatibility reactions of AKR and DBA/1 mice. (1957) (0)
Quantitationof FibrinogeniInfluxand FibrinDepositionand in Line 1 and Line 10 Guinea Pig Carcinomas1 (2006) (0)
Basophils and Mast Cells: Morphologic Insights into Their Biology, Secretory Patterns, and Function (Part 3 of 7) (1984) (0)
Nerve growth factor : A protease that can activate plasminogen ( mouse submandibular gland / fibrinolysis / urokinase / streptokinase / serine proteases ) (2004) (0)
Antibody enhances lymphocyte proliferation in guinea pigs immunized to express cutaneous basophil hypersensitivity. (1986) (0)
Granulocytes (the red, white, and blue) in hypersensitivity reactions: A review (1976) (0)
P R I M a R Y I M M U N I Z a T I O N of L Y M P H N O D E Cells I N (2003) (0)
Abstract 3600: NanoChannel-mediated communication between tumor cells and endothelium mediates metastatic parasitism (2014) (0)
Introduction--heterogeneity of the cellular immune response. (1979) (0)
Basophils and Mast Cells: Morphologic Insights into Their Biology, Secretory Patterns, and Function (Part 4 of 7) (1984) (0)
Contents, Vol. 66, Supplement 1, 1981 (1981) (0)
Pig Tumor-secreted Vascular Permeability Factor-Terminal Amino Acid Sequence of Guinea 2 Purification and NH Updated Version (2006) (0)
Table 35-3, Antigens with Highly Restricted Specificity (2003) (0)
236 BASOPHILS IN ALLERGIC CONTACT DERMATITIS (0)

This paper list is powered by the following services:

Other Resources About Harold F. Dvorak

en.wikipedia.org

What Schools Are Affiliated With Harold F. Dvorak?

Harold F. Dvorak is affiliated with the following schools:

Harold F. Dvorak's Academic­Influence.com Rankings